Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acorda Therapeutics (NQ: ACOR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acorda Therapeutics

< Previous 1 2 3 4 5 6 7 8 Next >
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
Acorda Therapeutics stock is falling hard on Tuesday after the company announced a bankruptcy filing and stalking horse bid agreement. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to check out all of the biggest pre-market stock movers worth watching on with the winners and losers of Tuesday! 
Via InvestorPlace
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
From Acorda Therapeutics
Via Business Wire
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
From Acorda Therapeutics Acorda Therapeutics, Inc.
Via Business Wire
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
From Acorda Therapeutics
Via Business Wire
Earnings Scheduled For April 1, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million. 
Via Benzinga
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
From Acorda Therapeutics
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Acorda Therapeutics Inc. (NASDAQ: ACOR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
From Acorda Therapeutics
Via Business Wire
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
From Acorda Therapeutics
Via Business Wire
Tom Burns Elected to the Acorda Therapeutics Board of Directors
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic with traders on Thursday as we go over the shares seeing the biggest movements this morning. 
Via InvestorPlace
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.